No abstract

No abstract

Methodology Retrospective observational cohort study. We reviewed medical records of diagnosed EOC patients (pts) who were eligible for SACT, between 2012 and 2018. Primary endpoint was overall survival (OS). Secondary endpoints were description of platinum sensibility patterns and lines of treatment (LOT). Descriptive analysis of main demographic, clinical and treatment variables were performed. Kaplan-Meier method was used for OS. Uni and multivariable analysis were done using Cox proportional hazard analysis Result(s)* We identified 268 EOC pts with median age of 66 (24-94). Debulking surgery was performed in 119 pts (44.4%). Most were stage III-IV FIGO (200, 74.6%) and had high-grade serous morphology (103, 38.6%). BRCA mutations (germline and/or somatic) were detected in 7.6% of 131 tested pts. A third of pts never relapsed (86, 32.1%). Platinum-based CT was the 1 st LOT in 173 pts (64,6%). After relapse or progression, primary platinum resistance (PPR) was present in 34 (19.7%), partial platinum sensibility in 29 (16.8%) and full platinum sensibility in 24 (13.9%). Of the 180 pts who progressed, 41 (22.8%) were submitted to 2 nd SACT and 20 (11.1%) to 3 rd SACT. Median number of LOT were 2 (1-8). Bevacizumab concomitant with CT was used in 45 pts (16.8%) at some point. PARPi was used in 23 (8.6%) pts as maintenance treatment after !2 platinum-based CT complete or partial response. Median OS was 25.5 months , which was significantly worse for more advanced disease and PPR . Conclusion* Our results confirm that EOC outcomes are modest and in line with other published cohorts. Multicentric realworld studies are needed to evaluate how innovative targeted therapies, recently introduced in the daily clinical practice, will change the course of this disease.

apatinib combined with chemotherapy plus PD-1 antibody drug (2/26), and apatinib combined with PD-1 antibody drug (9/26) and apatinib combined with chemotherapy plus radiotherapy (1/26). The median follow-up time was 5 months. The ORR and DCR were 47.3%(9/19) and 94.7%(18/19). The median PFS was not reached.In addition, 23 pts with ovarian cancer were enrolled in this study. Among them 15 pts were platinum-sensitive, 8 pts were platinum-resistant. The treatment regimens were: apatinib combined with chemotherapy (19/23), apatinib monotherapy (1/23), apatinib combined with chemotherapy drugs plus PD-1 antibody drug (1/23), apatinib combined with PD-1 antibody drug (1/23) and apatinib combined with PARPi (1/23). The median follow-up time was 6 months.The median PFS was 4 months.The ORR and DCR was 14.3%(3/21) and 85.7%(18/ 21).In this real-world study, the incidence of adverse reactions of ovarian cancer and cervical cancer was 79.6%. Grade 3 neutropenia, leukopenia, anemia, proteinuria and thrombocytopenia were observed in 2, 1, 5, 2 and 3 pts. Conclusion* In this real-world study, apatinib showed a favorable efficacy and safety profile in pts with gynecological cancer. It might lead to better survival benefit in treatment for gynecological cancer pts.

Introduction/Background* Secondary prevention of cervical cancer should remain a key priority for women's health globally for decades to come, especially in developing countries. A